ROCO
4169
Market cap333mUSD
May 05, Last price
160.00TWD
Name
Tcm Biotech International Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
TCM Biotech International Corp. is a biotechnology enterprise primarily focused on the research and development of pharmaceuticals aimed at preventing and treating liver conditions. The company boasts a diverse product lineup, encompassing solutions for osteoarthritis and osteoporosis, iron supplements, and treatments for urinary system ailments. Furthermore, its offerings extend to expectorants, mucolytic agents, anti-hypertensive preparations, and anti-diabetic medications. Beyond pharmaceuticals, the company also provides anti-adhesion systems, Pellefeel wound care systems, Philips non-invasive ventilators, various other medical devices, and functional foods. Founded in 1998, TCM Biotech International Corp. is headquartered in New Taipei City, Taiwan.
Key people
Huanqing Xu
Chairman of the Board · since 2015
Xiuming Wei
Chief Financial Officer · since 2023
Yajun Wang
General Manager, Director · since 2015
Zhenyao Chen
Deputy General Manager, Chief R&D Officer · since 2023
Shuya Yang
Head of Accounting, Corporate Governance Officer · since 2025
Cipei Chen
Director · since 2012
Jinji Chen
Director · since 2020
Yi Fang Xu
Director · since 2018
Huiyou Chen
Independent Director · since 2023
Independent Director · since 2023
Hengyi Liu
Independent Director · since 2023
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||